(Q51757343)

11 April 2018

title

Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. (English)

1 reference

11 April 2018

author name string

Sarah H Tannehill-Gregg

1

1 reference

11 April 2018

Thomas P Sanderson

2

1 reference

11 April 2018

Daniel Minnema

3

1 reference

11 April 2018

Richard Voelker

4

1 reference

11 April 2018

Borge Ulland

5

1 reference

11 April 2018

Samuel M Cohen

6

1 reference

11 April 2018

Lora L Arnold

7

1 reference

11 April 2018

Beth E Schilling

8

1 reference

11 April 2018

C Robbie Waites

9

1 reference

11 April 2018

Mark A Dominick

10

1 reference

11 April 2018

publication date

10 April 2007

1 reference

11 April 2018

published in

Toxicological Sciences

1 reference

11 April 2018

volume

98

1 reference

11 April 2018

issue

1

1 reference

11 April 2018

page(s)

258-270

1 reference

11 April 2018

Human bladder cancer: evidence for a potential irritation-induced mechanism

cites work

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

A review and biological risk assessment of sodium saccharin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

S-100 antigen labels neoplastic cells in liposarcoma and cartilaginous tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Cell proliferation in the bladder and implications for cancer risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Effects of PPARgamma and combined agonists on the urinary tract of rats and other species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Species comparison of the content and composition of urinary proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

PPARalpha agonist-induced rodent tumors: modes of action and human relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Histopathology of the spleen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Trend and homogeneity analyses of proportions and life table data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM083

21 January 2018

Identifiers

DOI

10.1093/TOXSCI/KFM083

1 reference

11 April 2018

1 reference

11 April 2018